NCT02716116 2026-02-25
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Takeda
Phase 1/2 Active not recruiting
Clinical Trials
6 trialsNCT04051827 2025-07-28
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Takeda
Phase 1 Completed
NCT03807778 2025-05-15
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
Takeda
Phase 1 Active not recruiting
NCT04129502 2025-04-22
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Takeda
Phase 3 Active not recruiting
NCT04535557 2022-09-30
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
Takeda
Approved for marketing
NCT04576208 2020-12-17
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
Takeda
Phase 2 Withdrawn